US Patent Issued to NovoMab BioPharmaceuticals on April 21 for "Antibody that specifically binds to human CTLA4 and medicaments and kits comprising the same" (Chinese Inventors)

ALEXANDRIA, Va., April 21 -- United States Patent no. 12,606,624, issued on April 21, was assigned to NovoMab BioPharmaceuticals Inc (Nanjing, China).

"Antibody that specifically binds to human CTLA4 and medicaments and kits comprising the same" was invented by Weiliang Zhuang (Nanjing, China) and Lili Pei (Nanjing, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention discloses an antibody that specifically binds to human CTLA4, comprising three complementarily-determining regions; the three complementarity-determining regions are respectively: CDR1 with an amino acid sequence as shown in SEQ ID NO: 1, CDR2 with an amino acid sequence as shown in SEQ ID NO: 2, and CDR3 with an amino aci...